These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 18070151)

  • 1. High serum YKL-40 level in a cohort of octogenarians is associated with increased risk of all-cause mortality.
    Johansen JS; Pedersen AN; Schroll M; Jørgensen T; Pedersen BK; Bruunsgaard H
    Clin Exp Immunol; 2008 Feb; 151(2):260-6. PubMed ID: 18070151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum YKL-40 predicts adverse clinical outcomes in patients with chronic heart failure.
    Bilim O; Takeishi Y; Kitahara T; Ishino M; Sasaki T; Suzuki S; Shishido T; Kubota I
    J Card Fail; 2010 Nov; 16(11):873-9. PubMed ID: 21055651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia.
    Bergmann OJ; Johansen JS; Klausen TW; Mylin AK; Kristensen JS; Kjeldsen E; Johnsen HE
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8644-52. PubMed ID: 16361549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The inflammatory biomarker YKL-40 as a new prognostic marker for all-cause mortality in patients with heart failure.
    Harutyunyan M; Christiansen M; Johansen JS; Køber L; Torp-Petersen C; Kastrup J
    Immunobiology; 2012 Jun; 217(6):652-6. PubMed ID: 22209156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
    Schmidt H; Johansen JS; Gehl J; Geertsen PF; Fode K; von der Maase H
    Cancer; 2006 Mar; 106(5):1130-9. PubMed ID: 16456816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease.
    Vind I; Johansen JS; Price PA; Munkholm P
    Scand J Gastroenterol; 2003 Jun; 38(6):599-605. PubMed ID: 12825867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease.
    Kastrup J; Johansen JS; Winkel P; Hansen JF; Hildebrandt P; Jensen GB; Jespersen CM; Kjøller E; Kolmos HJ; Lind I; Nielsen H; Gluud C;
    Eur Heart J; 2009 May; 30(9):1066-72. PubMed ID: 19270316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-6, but not TNF-α, increases plasma YKL-40 in human subjects.
    Nielsen AR; Plomgaard P; Krabbe KS; Johansen JS; Pedersen BK
    Cytokine; 2011 Jul; 55(1):152-5. PubMed ID: 21478032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: a prognostic study within the CLARICOR trial.
    Harutyunyan M; Gøtze JP; Winkel P; Johansen JS; Hansen JF; Jensen GB; Hilden J; Kjøller E; Kolmos HJ; Gluud C; Kastrup J
    Immunobiology; 2013 Jul; 218(7):945-51. PubMed ID: 23294528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma.
    Schmidt H; Johansen JS; Sjoegren P; Christensen IJ; Sorensen BS; Fode K; Larsen J; von der Maase H
    J Clin Oncol; 2006 Feb; 24(5):798-804. PubMed ID: 16391295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma.
    Biggar RJ; Johansen JS; Smedby KE; Rostgaard K; Chang ET; Adami HO; Glimelius B; Molin D; Hamilton-Dutoit S; Melbye M; Hjalgrim H
    Clin Cancer Res; 2008 Nov; 14(21):6974-8. PubMed ID: 18980992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival.
    Johansen JS; Christensen IJ; Riisbro R; Greenall M; Han C; Price PA; Smith K; Brünner N; Harris AL
    Breast Cancer Res Treat; 2003 Jul; 80(1):15-21. PubMed ID: 12889595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The inflammatory biomarker YKL-40 at admission is a strong predictor of overall mortality.
    Mygind ND; Iversen K; Køber L; Goetze JP; Nielsen H; Boesgaard S; Bay M; Johansen JS; Nielsen OW; Kirk V; Kastrup J
    J Intern Med; 2013 Feb; 273(2):205-16. PubMed ID: 23140269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer.
    Chen IM; Johansen AZ; Dehlendorff C; Jensen BV; Bojesen SE; Pfeiffer P; Bjerregaard JK; Nielsen SE; Andersen F; Holländer NH; Yilmaz MK; Rasmussen LS; Johansen JS
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):176-184. PubMed ID: 31685562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer.
    Yamac D; Ozturk B; Coskun U; Tekin E; Sancak B; Yildiz R; Atalay C
    Adv Ther; 2008 Aug; 25(8):801-9. PubMed ID: 18670741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between plasma insulin-like growth factor-I and the markers of inflammation interleukin 6, C-reactive protein and YKL-40 in an elderly background population.
    Andreassen M; Raymond I; Hildebrandt P; Kistorp C; Rathcke C; Vestergaard H; Faber J; Kristensen LO
    Inflamm Res; 2010 Jul; 59(7):503-10. PubMed ID: 20047081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low grade inflammation as measured by levels of YKL-40: association with an increased overall and cardiovascular mortality rate in an elderly population.
    Rathcke CN; Raymond I; Kistorp C; Hildebrandt P; Faber J; Vestergaard H
    Int J Cardiol; 2010 Aug; 143(1):35-42. PubMed ID: 19223085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival.
    Roslind A; Johansen JS; Christensen IJ; Kiss K; Balslev E; Nielsen DL; Bentzen J; Price PA; Andersen E
    Int J Cancer; 2008 Feb; 122(4):857-63. PubMed ID: 17957792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships between increased circulating YKL-40, IL-6 and TNF-α levels and phenotypes and disease activity of primary Sjögren's syndrome.
    Chen C; Liang Y; Zhang Z; Zhang Z; Yang Z
    Int Immunopharmacol; 2020 Nov; 88():106878. PubMed ID: 32791244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of YKL-40 acute-phase protein and interleukin-6 levels in periodontal disease.
    Keles ZP; Keles GC; Avci B; Cetinkaya BO; Emingil G
    J Periodontol; 2014 Sep; 85(9):1240-6. PubMed ID: 24635545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.